AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation
therapy versus the standard antiplatelet therapy after transcatheter aortic valve
implantation in patients with aortic stenosis. The trial will assess the efficacy of direct
oral anticoagulation (DOAC) therapy compared to the standard single antiplatelet therapy to
prevent degeneration of the valve and its safety in co-primary endpoints with blinded
endpoint adjudication. The effect of DOAC therapy on hard clinical outcomes will be assessed
during long-term follow-up.